Radiation necrosis risk assessment after stereotactic radiation therapy for brain metastasis


Creative Commons License

Yakar M. Ç., Etiz D.

MARMARA MEDICAL JOURNAL, vol.38, no.3, pp.235-241, 2025 (ESCI, Scopus, TRDizin)

  • Publication Type: Article / Article
  • Volume: 38 Issue: 3
  • Publication Date: 2025
  • Journal Name: MARMARA MEDICAL JOURNAL
  • Journal Indexes: Scopus, Emerging Sources Citation Index (ESCI), Academic Search Premier, CINAHL, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.235-241
  • Open Archive Collection: AVESIS Open Access Collection
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

Objective: To investigate factors influencing the occurrence of radiation necrosis (RN) in patients receiving fractionated stereotactic
radiotherapy (fSRT) for brain metastases.
Patients and Methods: Forty patients underwent linear accelerator-based fSRT from January 2018 to December 2023. RN and treatment
response were monitored using magnetic resonance imaging (MRI), with toxicity graded by the Common Terminology Criteria for
Adverse Events (CTCAE) version 5.0 and oncological response was evaluated by the Response Evaluation Criteria in Solid Tumors
(RECIST) criteria.
Results: At a median follow-up of 12 months, RN occurred in 4 (10%) patients. Two patients had asymptomatic grade 1 RN, while
two required steroids for grade 2 RN. Univariate analysis showed significant factors for RN: history of repeated fSRT (p=0.020), >1
metastatic lesion (p=0.022), age (p=0.016), and brain V30 (p=0.022). Multivariate analysis confirmed that repeated fSRT (p=0.02) and
age (p=0.002) were significant.
Conclusion: Radiation necrosis is a major concern in fSRT for brain metastases. Repeated fSRT, multiple metastatic lesions, age, and
higher brain V30 values increase RN risk. Individualized treatment planning, especially considering dose-volume parameters, may
help reduce this risk. Larger prospective studies are needed to confirm these findings and optimize RN mitigation strategies.